newsfilter
← Earnings
Earnings Releases·

Atossa Therapeutics — Third Quarter 2026 Earnings Summary

Atossa Therapeutics reported total operating expenses of $5.9 million for the third quarter of 2026, a decrease from $9.3 million in the same period of 2025. The company entered into a Stapled Contingent Value Rights agreement on October 8, 2026, entitling shareholders to 25% of net proceeds up to $50 million from the sale of a future FDA priority review voucher. Anticipated milestones include FDA clearance for Investigational New Drug applications for (Z)-endoxifen in Duchenne Muscular Dystrophy and McCune-Albright Syndrome by early 2027, with Phase 2 trials expected to begin that year. Additionally, the company plans to present Karisma trial results and I-SPY2 study data at the San Antonio Breast Cancer Symposium in December 2026.

Company
ATOSSA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology